Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
Abstract Polymyxin B (PMB) has reemerged as a last‐line therapy for infections caused by multidrug‐resistant gram‐negative pathogens, but dosing is challenging because of its narrow therapeutic window and pharmacokinetic (PK) variability. Population PK (POPPK) models based on suitably powered clinic...
Saved in:
Main Authors: | Patrick O. Hanafin (Author), Roger L. Nation (Author), Marc H. Scheetz (Author), Alexandre P. Zavascki (Author), Ana M. Sandri (Author), Andrea L. Kwa (Author), Benjamin P. Z. Cherng (Author), Christine J. Kubin (Author), Michael T. Yin (Author), Jiping Wang (Author), Jian Li (Author), Keith S. Kaye (Author), Gauri G. Rao (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
by: Roger L. Nation, et al.
Published: (2019) -
A Review of the Clinical Pharmacokinetics of Polymyxin B
by: Sean N. Avedissian, et al.
Published: (2019) -
Shifting Gears: The Future of Polymyxin Antibiotics
by: Justin R. Lenhard, et al.
Published: (2019) -
Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
by: Danhong Liang, et al.
Published: (2023) -
Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae
by: Patrick O. Hanafin, et al.
Published: (2023)